Acute Porphyria Drugs

J07BM03 - Papillomavirus (Human Types 6, 11, 16, 18, 31, 33, 45, 52, 58)

Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the papillomavirus vaccine, no porphyrinogenic effects are expected.
Chemical description
Protein in the form of virus-like particles produced by recombinant technology.
Therapeutic characteristics
Indicated for protection against contitions caused by nine types of human papillomavirus in individuals from the age of nine. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BM or go back.
References
# Citation details PMID
*Government bodies
1. European Medicines Agency (EMA). SmPC Gardasil 9.
2. Norwegian institute of public health. Vaccines and vaccination.

Tradenames

Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil 9 vaccine Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Gardasil Vaccines
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙